2014 Analysis of Shimadzu in the Worldwide Diagnostic Imaging Market
This strategic assessment of Shimadzu, one of the world's leading diagnostic imaging companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The new report from Venture Planning Group presents a comprehensive analysis of the company's performance, capabilities, goals, and strategies in the global diagnostic imaging market.
Contains 65 pages and 6 tables
Contains 65 pages and 6 tables
SECTION I: EXECUTIVE SUMMARY
A 3-15 page synopsis of key sections.
SECTION II: BUSINESS ORGANIZATION
History of the company’s diagnostic imaging business evolution, which is important to understanding the corporate culture, management mentality and strategies.
Recent acquisitions, divestitures and major organizational changes.
Current organizational structure.
SECTION III: SENIOR MANAGEMENT
Names, titles and background of key executives.
SECTION IV: FACILITIES AND EMPLOYEES
Administrative, manufacturing and R&D facilities in the U.S. and abroad.
Manufacturing practices.
New plants under construction.
The U.S. and international work force size and distribution.
SECTION V: TECHNOLOGICAL KNOW-HOW
Internally developed and acquired diagnostic imaging and related technologies, including X-ray, ultrasound, MRI, CT, nuclear medicine, PET, PACS, and others.
SECTION VI: PRODUCT PORTFOLIO
Placements and installed base of major systems in the U.S. and abroad, by modality.
Review of major product lines.
Applications, advantages and weaknesses of leading products.
SECTION VII: MARKETING TACTICS
Promotional tactics.
Distribution approaches.
Product service and support.
Customer relations.
SECTION VIII: FINANCIAL ANALYSIS
Estimated sales and operating profit by division, geographic region and product line.
Five-year sales and operating profit performance.
SECTION IX: R&D EXPENDITURES AND MAJOR PROGRAMS
Estimated R&D budget.
Research facilities and staff.
New technologies, systems and applications in development.
SECTION X: COLLABORATIVE ARRANGEMENTS
Joint ventures, distribution, O.E.M. and licensing partners, both industrial and academic.
Terms of collaborative agreements and specific products involved.
SECTION XI: STRATEGIC DIRECTION
Specific business, new product development and marketing strategies.
Anticipated acquisitions, joint ventures and divestitures.
A 3-15 page synopsis of key sections.
SECTION II: BUSINESS ORGANIZATION
History of the company’s diagnostic imaging business evolution, which is important to understanding the corporate culture, management mentality and strategies.
Recent acquisitions, divestitures and major organizational changes.
Current organizational structure.
SECTION III: SENIOR MANAGEMENT
Names, titles and background of key executives.
SECTION IV: FACILITIES AND EMPLOYEES
Administrative, manufacturing and R&D facilities in the U.S. and abroad.
Manufacturing practices.
New plants under construction.
The U.S. and international work force size and distribution.
SECTION V: TECHNOLOGICAL KNOW-HOW
Internally developed and acquired diagnostic imaging and related technologies, including X-ray, ultrasound, MRI, CT, nuclear medicine, PET, PACS, and others.
SECTION VI: PRODUCT PORTFOLIO
Placements and installed base of major systems in the U.S. and abroad, by modality.
Review of major product lines.
Applications, advantages and weaknesses of leading products.
SECTION VII: MARKETING TACTICS
Promotional tactics.
Distribution approaches.
Product service and support.
Customer relations.
SECTION VIII: FINANCIAL ANALYSIS
Estimated sales and operating profit by division, geographic region and product line.
Five-year sales and operating profit performance.
SECTION IX: R&D EXPENDITURES AND MAJOR PROGRAMS
Estimated R&D budget.
Research facilities and staff.
New technologies, systems and applications in development.
SECTION X: COLLABORATIVE ARRANGEMENTS
Joint ventures, distribution, O.E.M. and licensing partners, both industrial and academic.
Terms of collaborative agreements and specific products involved.
SECTION XI: STRATEGIC DIRECTION
Specific business, new product development and marketing strategies.
Anticipated acquisitions, joint ventures and divestitures.
More Publications
2014 Analysis of the Argentinean Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies
US$ 5,360.00
November 2013
509 pages
World Immunoprotein Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Market Shares, Sales Forecasts, and Strategic Profiles of Key Players
US$ 6,800.00
January 2014
297 pages
2014-2018 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing
US$ 7,600.00
November 2014
880 pages
Future Horizons and Growth Strategies in the French Molecular Diagnostics Market 2015: Supplier Shares and Country Forecasts
US$ 5,360.00
June 2015
1125 pages
Future Horizons and Growth Strategies in the German Molecular Diagnostics Market 2015: Supplier Shares and Country Forecasts
US$ 5,360.00
June 2015
1125 pages
